Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients.
暂无分享,去创建一个
S. Arbuck | C. Takimoto | J. Grem | C. Allegra | N. Berger | J. Wright | J. Shapiro | J. M. Hamilton | A. Chen | S. J. Berger | D. Gosky | A. Guemei | R. Band | B. Monahan | G. Morrison | N. Harold | M. Quinn | J. Cottrell | V. Llorens | H. Hehman | A. Ismail | D. Flemming | H. Hirota | J. Hamilton | B. P. Monahan
[1] P. Houghton,et al. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] L. Wienkers,et al. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[3] R. Goldberg,et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Robert,et al. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes Differential hydrolysis for the lactone and carboxylate forms , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.
[5] P. Hérait,et al. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Verweij,et al. Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Ratain,et al. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] D. V. Von Hoff,et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] T. Chou,et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Berger,et al. Mutagenic activity of topoisomerase I inhibitors , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] S. Culine,et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] K. Eguchi,et al. A Pharmacokinetic and Pharmacodynamic Analysis of CPT‐11 and Its Active Metabolite SN‐38 , 1995, Japanese journal of cancer research : Gann.
[13] K. Itoh,et al. Pharmacological Correlation between Total Drug Concentration and Lactones of CPT‐11 and SN‐38 in Patients Treated with CPT‐11 , 1995, Japanese journal of cancer research : Gann.
[14] J. Robert,et al. Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. , 1994, Journal of chromatography. B, Biomedical applications.
[15] S. Culine,et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. , 1994, Cancer research.
[16] M. Ratain,et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. , 1994, Cancer research.
[17] P. Hérait,et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. , 1994, Journal of the National Cancer Institute.
[18] H. Hochster,et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] L. Grochow,et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. , 1994, Cancer research.
[20] G. Weiss,et al. Phase I and pharmacokinetic trial of weekly CPT-11. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] H. Ohmatsu,et al. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. , 1992, Journal of the National Cancer Institute.
[22] T. Yoshimoto,et al. CPT-11 converting enzyme from rat serum: purification and some properties. , 1991, Journal of pharmacobio-dynamics.
[23] J. Verweij,et al. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. , 1997, British Journal of Cancer.
[24] S. Culine,et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] P. Hérait,et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.